ABCG2 and cancer: Compared to the control group, several important drug resistant metabolic pathways were affected in the SW620 PD_R experimental group including purine metabolism, ABC transporters, pyrimidine metabolism, sphingolipid signaling pathway, beta-alanine metabolism, glutathione metabolism, arginine biosynthesis, and choline metabolism in cancer (Supplementary Table S4).